Methods of treatment of angina pectoris
Автор: Arzikulov Abduraim Shamshievich, Yusupov Kakhramon Mukhitdinovich, Abdurahimov Abdukhalim Kholiddinovich, Nugmanov Ozodbek Zhuraboy Ugli
Журнал: Re-health journal.
Статья в выпуске: 3,1 (7), 2020 года.
Бесплатный доступ
Angina pectoris is the most common manifestation of myocardial ischaemia and is often a consequence of coronary artery disease (CAD). Angina pectoris (Latin for chest pain) is pain that is caused by injury to the heart muscle (myocardium) during times of increased cardiac activity as a result of impaired blood flow and reduced oxygen supply. It is a common disease in the population of our planet. Complications are very dangerous. This article discusses effective methods of treatment of this disease.
Angina pectoris, myocardial ischaemia, coronary artery disease, myocardium, stenokardiya, yurak ishemik kasalligi, koronar arteriya, miokard
Короткий адрес: https://sciup.org/14125591
IDR: 14125591 | DOI: 10.24411/2181-0443/2020-10101
Список литературы Methods of treatment of angina pectoris
- Chong, C.-R., Ong, G. J., & Horowitz, J. D. (2016). Emerging drugs for the treatment of angina pectoris. Expert Opinion on Emerging Drugs, 21(4), 365-376.
- Ong, P., Athanasiadis, A., & Sechtem, U. (2016). Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction. Cardiovascular Drugs and Therapy, 30(4), 351- 356.
- Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003. RE-HEALTH JOURNAL 3-2020 7.
- Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensinconverting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme a reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation. 2004;109:53-8.
- Chen JW1, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974-982.
